Key Highlights

  • 32.19% of the float in Intellia (NASDAQ:NTLA) is sold short, the highest of the four, with 9.5 days to cover at USD 11.38 on October 16, 2026, per published market data. The lonvo-z FDA action date is March 10, 2027, per the September 8 8-K.
  • 29.50% of the float in Recursion (NASDAQ:RXRX) is sold short, with 6.1 days to cover, after a USD 200 million offering priced at USD 3.25 on October 15, 2026, per the 8-K, took the stock down 8.18% to USD 3.82. More data are due November 2.
  • 27.92% of the float in Novavax (NASDAQ:NVAX) is sold short, with 8.1 days to cover, after a 10.88% decline to USD 11.43 on October 16 that followed a 20.08% rally on October 5. Cash was USD 723.9 million at June 30, 2026.
  • 26.39% of the float in Tango Therapeutics (NASDAQ:TNGX) is sold short, the lowest of the four, with the longest days to cover at 12.5. Updated pancreatic cancer data are due at ESMO, October 23 to 27, 2026, and cash was USD 1.0 billion.

Intellia (NASDAQ:NTLA)

A short position into an FDA date is a bet that approval is priced in or that the market sells the news. What separates Intellia is the longest runway to a decision: March 10, 2027 is 145 days away, own arithmetic from October 16, and the FDA told the company it does not currently plan an advisory committee. Phase 3 data showed an 87% reduction in monthly attack rates against placebo, with 62% of patients attack-free over six months. Shorts focus on the second program, since the August 6, 2026 release said liver transaminase elevations were highest in nex-z patients with one HLA allele. FINRA data for September 15 recorded 46,681,609 shares short, which is 14.1 days to cover and USD 531 million at the current quote, own arithmetic. Cash of USD 628.4 million equals 39.5% of market capitalisation, own arithmetic, and is guided into 2028. So what: Intellia (NASDAQ:NTLA) closed October 15 at the bottom of its 50-day range, so shorts lead until approval is priced, and approval could bring an equity raise.

Recursion (NASDAQ:RXRX)

Recursion is where the squeeze thesis met a financing event. What separates it is the offering: 61,540,000 Class A shares at USD 3.25 added 11.5% to the 535.34 million outstanding, own arithmetic, and the October 16 quote of USD 3.82 implies an October 15 close of USD 4.16, so the offering priced 21.9% below it, own arithmetic. FINRA data for September 30 show 157,938,412 shares short, down 11.63% from September 15, equal to USD 603 million at the current quote. Offerings can lower reported short interest when arbitrageurs receive shares to close positions, a structural explanation not disclosed by the company. The REC-4881 study showed polyp burden reductions in 13 of 15 evaluable patients, a median of 47%, while 4 of 26 patients had Grade 3 treatment-related events. Cash of USD 561 million at September 30, preliminary and unaudited, extends runway into 2029, and Sanofi's option on a first candidate triggered a USD 10 million milestone. A director sold 25,000 shares on October 8. So what: Recursion (NASDAQ:RXRX) has less financing risk for shorts to price, and covering depends on the November 2 data.

Novavax (NASDAQ:NVAX)

Novavax is trading as a lottery ticket on outbreak headlines, though it markets no plague vaccine. What separates it is that its squeeze already happened and reversed. The shares rose 20.08% on October 5, 2026 to USD 12.56 on a rival's late-stage pneumonia vaccine result, unconfirmed plague reports and short covering, then fell 12% on October 6 when the World Health Organization said contacts tested negative. The October 16 decline of 10.88% has no company-specific catalyst in the filings and releases reviewed through that date. FINRA data show 46,046,946 shares short on September 30, USD 526 million at USD 11.43, own arithmetic. Second quarter revenue of USD 56.7 million fell 76% because the prior year held USD 202 million of milestone revenue, and the stockholders' deficit was USD 190.7 million. So what: Novavax (NASDAQ:NVAX) carries USD 723.9 million of cash against USD 291.5 million of long-term debt, and Sanofi milestones of USD 125 million and USD 75 million are its dated upside.

Tango Therapeutics (NASDAQ:TNGX)

Tango has the nearest scheduled catalyst and the slowest exit for shorts. What separates it is the data event: ESMO runs from October 23 to 27, 2026, seven days from October 16, own arithmetic. Days to cover of 12.5 implies average volume of 3.56 million shares on a 44.5 million share position, own arithmetic, so strong data could force buying into thin supply. The June 8 release reported a 92% objective response rate in 11 of 12 evaluable pancreatic patients for vopimetostat with daraxonrasib, and the FDA approved daraxonrasib on August 26, 2026. The shorts' rationale is not disclosed; supportable concerns are small cohorts and dependence on a partner drug. Cash of USD 1.0 billion covers 4.5 years at the second quarter loss annualised, own arithmetic, before Phase 3 costs. So what: Tango Therapeutics (NASDAQ:TNGX) has a USD 1.01 billion short position equal to its cash, and ESMO decides which side benefits. Piper Sandler cut the stock to Neutral on May 15, 2026.

Where Things Stand

Tango Therapeutics (NASDAQ:TNGX) reports data first, at ESMO from October 23, 2026. Recursion (NASDAQ:RXRX) follows with REC-4881 data on November 2 and estimated earnings on November 4. Intellia (NASDAQ:NTLA) is estimated to report on November 5, before its March 10, 2027 FDA date. Novavax (NASDAQ:NVAX) reports in early November, unconfirmed. Ranked by days to cover, Tango leads at 12.5, then Intellia at 9.5, Novavax at 8.1 and Recursion at 6.1, so Tango has the slowest exit and Recursion the fastest. No setup combines a near catalyst with a fast exit, and short interest alone does not move prices. Ranked by cash as a share of market capitalisation, Intellia leads at 39.5%, then Novavax at 38.5%, Recursion at 27.4% and Tango at 26.2%, own arithmetic on reported cash.